The Top 5 Most-Listened to Podcasts of 2024

The top 5 podcast episodes of the year showcase pivotal moments and insights shaping the biosimilar market. Topics range from the approval of the first denosumab biosimilars, which are set to expand treatment options in osteoporosis care, to the complexities of patent thickets that continue to hinder biosimilar competition. Episodes also highlighted strategies for overcoming barriers to biosimilar adoption, with a focus on education, access, and market innovation, as well as addressing challenges in affordability. Expert guests discuss the evolving regulatory landscape, market dynamics, and predict future trends, offering valuable insights for stakeholders navigating this transformative sector. And while we of course recommend you listen to all our episodes, if you're looking for some of this year's highlights, stay tuned.

Here are the top 5 episodes of Not So Different from 2024.

Show notes

Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved

The Center for Biosimilars^®, supported by Sandoz, discusses the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), which were approved in March 2024 for different indications. Experts Colin C. Edgerton, MD, a rheumatologist at Articularis Healthcare Group and a member of the American College of Rheumatology ultrasound task force, and Jeffrey Curtis, MD, MS, MPH, a professor, rheumatologist, and epidemiologist at the University of Alabama at Birmingham and a former member of the FDA Arthritis Advisory Committee, share insights on the evolving osteoporosis treatment landscape and how these biosimilars could enhance access to denosumab therapy.

To read the full article, click here.

Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars

The US patent system has created significant barriers to biosimilar competition, with legal strategies like patent thickets and litigation delaying market access for biosimilars, as seen with Stelara (reference ustekinumab) and Humira (reference adalimumab). On this particular episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, explored the complexities of the patent system and discusses potential reforms to promote competition and innovation in the biosimilar market.

To read the full article, click here.

Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

This next episode of Not So Different explores key insights from the Festival of Biologics USA and the Cardinal Health Biosimilars Report, emphasizing sustainability and challenges in biosimilar adoption and affordability. Joined by Dracey Poore, Director of Biosimilars at Cardinal Health, the discussion delved into prescriber trends, access barriers, and strategies to foster a competitive biosimilar market. It highlighted the importance of education, market innovation, and collaborative efforts to improve patient access to these critical medications while promoting a sustainable health care system.

To read the full article, click here.

Number 2: Biosimilars in America: Overcoming Barriers and Maximizing Impact

This next episode delved into the complexities of the US biosimilars market, examining legislative influences, payer and provider adoption factors, and strategies to address industry challenges. Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora, offered expert insights on navigating the regulatory landscape, understanding economic and clinical considerations, and improving market access for biosimilars. The discussion highlighted opportunities to enhance biosimilar adoption, reduce health care costs, and improve patient outcomes, making it an essential listen for stakeholders across the health care continuum.

To read the full article, click here.

Number 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024

In this January 2024 episode, Julie Reed, executive director of the Biosimilars Forum, discusses how recent advancements, such as the approval of the first on-body pegfilgrastim biosimilar and the growing adoption of adalimumab biosimilars, are reshaping the biosimilar market. Reed shares insights on evolving market dynamics, regulatory challenges, and future strategies, offering predictions on how these developments will influence investment decisions, market access, and patient care in the years ahead. It may be the end of the year but it's never to late to reflect on how you thought the year would go.

To read the full article, click here.